Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Year-over-year research & development expense growth
Latest
0.00%
↑ 100% vs avg
Percentile
P44
Within normal range
Streak
1 qtr
Consecutive growthStable
Average
-1.43%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | -100.00% |
| Q2 2025 | 9.46% |
| Q1 2025 | -7.94% |
| Q4 2024 | -21.99% |
| Q3 2024 | 4.14% |
| Q2 2024 | -18.92% |
| Q1 2024 | -27.39% |
| Q4 2023 | 6.73% |
| Q3 2023 | -46.24% |
| Q2 2023 | 6.42% |
| Q1 2023 | -4.87% |
| Q4 2022 | 7.20% |
| Q3 2022 | -1.86% |
| Q2 2022 | 10.81% |
| Q1 2022 | 7.88% |
| Q4 2021 | -7.85% |
| Q3 2021 | 10.93% |
| Q2 2021 | 22.70% |
| Q1 2021 | 17.84% |
| Q4 2020 | 4.22% |
| Q3 2020 | 18.72% |
| Q2 2020 | -7.56% |
| Q1 2020 | 3.38% |
| Q4 2019 | 14.82% |
| Q3 2019 | 2.30% |
| Q2 2019 | -21.77% |
| Q1 2019 | -7.59% |
| Q4 2018 | 4.61% |
| Q3 2018 | -1.57% |
| Q2 2018 | 2.53% |
| Q1 2018 | -2.42% |
| Q4 2017 | 8.25% |
| Q3 2017 | -3.69% |
| Q2 2017 | 14.48% |
| Q1 2017 | -0.56% |
| Q4 2016 | -16.10% |
| Q3 2016 | 8.88% |
| Q2 2016 | 43.84% |
| Q1 2016 | 10.91% |